# Lenvatinib and Pembrolizumab Simultaneous Combination Study

> **NCT03609359** · PHASE2 · COMPLETED · sponsor: **National Cancer Center Hospital East** · enrollment: 29 (actual)

## Conditions studied

- Advanced Gastric Cancer

## Interventions

- **DRUG:** Lenvatinib
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03609359
- **Lead sponsor:** National Cancer Center Hospital East
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-03
- **Primary completion:** 2021-04-30
- **Final completion:** 2021-04-30
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2025-04-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03609359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03609359, "Lenvatinib and Pembrolizumab Simultaneous Combination Study". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03609359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*